Markus Ziener
Director of Finance/CFO at Software AG-Stiftung
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter M. Schnell | M | - |
Software AG-Stiftung
 Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Achim Grenz | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Johannes Stellmann | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Dirk Kannacher | M | - |
GLS Gemeinschaftsbank eG
 GLS Gemeinschaftsbank eG Regional BanksFinance GLS Gemeinschaftsbank eG provides banking services. It offers loans to projects like independent schools and kindergartens, organic farms, institutions using therapeutic pedagogy, nursing homes, projects for the unemployed, health-food stores and communal living projects, as well as sustainable businesses. The company was founded in 1974 and is headquartered in Bochum, Germany. | - |
| Aysel Osmanoglu | M | - |
GLS Gemeinschaftsbank eG
GLS Gemeinschaftsbank eG Regional BanksFinance GLS Gemeinschaftsbank eG provides banking services. It offers loans to projects like independent schools and kindergartens, organic farms, institutions using therapeutic pedagogy, nursing homes, projects for the unemployed, health-food stores and communal living projects, as well as sustainable businesses. The company was founded in 1974 and is headquartered in Bochum, Germany. | - |
| Christina Opitz | F | - |
GLS Gemeinschaftsbank eG
GLS Gemeinschaftsbank eG Regional BanksFinance GLS Gemeinschaftsbank eG provides banking services. It offers loans to projects like independent schools and kindergartens, organic farms, institutions using therapeutic pedagogy, nursing homes, projects for the unemployed, health-food stores and communal living projects, as well as sustainable businesses. The company was founded in 1974 and is headquartered in Bochum, Germany. | - |
| Thomas Bieri | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Peter Heusser | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Hilmar Dahlem | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Hans Rahmann | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Janine Hofmann | F | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Horst Kinzinger | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Paul Scigalla | M | 79 |
Ruprecht-Karls-Universität Heidelberg
| 32 years |
| Sandra Reich | M | 47 |
GLS Gemeinschaftsbank eG
GLS Gemeinschaftsbank eG Regional BanksFinance GLS Gemeinschaftsbank eG provides banking services. It offers loans to projects like independent schools and kindergartens, organic farms, institutions using therapeutic pedagogy, nursing homes, projects for the unemployed, health-food stores and communal living projects, as well as sustainable businesses. The company was founded in 1974 and is headquartered in Bochum, Germany. | - |
| Jürgen Schweiß-Ertl | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Götz E. Rehn | M | - |
Software AG-Stiftung
Software AG-Stiftung Investment Trusts/Mutual FundsMiscellaneous Software AG-Stiftung operates as an independent charitable non-profit organization. It funds projects carried out by non-profit organizations that provide benefit to the community. The company is headquartered in Darmstadt, Germany. | - |
| Thomas Jorberg | M | - |
GLS Gemeinschaftsbank eG
GLS Gemeinschaftsbank eG Regional BanksFinance GLS Gemeinschaftsbank eG provides banking services. It offers loans to projects like independent schools and kindergartens, organic farms, institutions using therapeutic pedagogy, nursing homes, projects for the unemployed, health-food stores and communal living projects, as well as sustainable businesses. The company was founded in 1974 and is headquartered in Bochum, Germany. | - |
| Irene Reifenhäuser-Karnath | F | - |
GLS Gemeinschaftsbank eG
GLS Gemeinschaftsbank eG Regional BanksFinance GLS Gemeinschaftsbank eG provides banking services. It offers loans to projects like independent schools and kindergartens, organic farms, institutions using therapeutic pedagogy, nursing homes, projects for the unemployed, health-food stores and communal living projects, as well as sustainable businesses. The company was founded in 1974 and is headquartered in Bochum, Germany. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ralf Eisenhauer | M | 55 |
Ruprecht-Karls-Universität Heidelberg
| 6 years |
| Cathal Friel | M | 59 |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 13 years |
| Alain Munoz | M | 75 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Anthony Culverwell | M | 68 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 years |
| Stephen Joyce | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| David Allmond | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 years |
| Michael Sandritter | M | - |
Duale Hochschule Baden-Württemberg Mannheim
| 4 years |
| Felix Kratz | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Thomas Carell | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Mona Welschof | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Donald Stern | M | 78 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Helmut Hufnagel | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| George Hampton | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Michele Bellandi | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Stephen Wills | M | 67 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 4 years |
| Patrick Jordan | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Kieran Rooney | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Jordi Casals | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Andreas Maderna | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| John McEvoy | M | 37 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Julie Eastwood | F | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Xudong Zhao | M | - |
Ruprecht-Karls-Universität Heidelberg
| 1 years |
| Simone Faath | F | 58 |
Ruprecht-Karls-Universität Heidelberg
| 1 years |
| Benita Gräfin von der Schulenburg | F | - |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Helen Phillips | M | - |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Derval O'Carroll | F | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Silvia Fazio | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Jochen Hummel | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Rolf Wiswesser | M | - |
Ruprecht-Karls-Universität Heidelberg
| 5 years |
| Achim Schäffler | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Youming Zhang | M | 60 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Oliver Wintermantel | M | - |
Ruprecht-Karls-Universität Heidelberg
| 6 years |
| Harry Thomas Stratford | M | 54 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 3 years |
| Patrick Volkert Vink | M | 60 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | - |
| Ilinca Rosetti | M | 50 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Wolfgang Lust | M | 54 |
GeckoGroup AG
 GeckoGroup AG Alternative Power GenerationUtilities GeckoLogic GmbH designs and installs solar photovoltaic systems for homes, businesses, government facilities, and commercial buildings. The company also develops PV components including modules and monitoring systems. GeckoLogic specializes in the planning of private solar electricity power stations, installation planning, and implementation. The company was founded in 2002 and is headquartered in Wetzlar, Germany. | - |
| Annelies Goos | F | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Heiko Carrie | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Cory Gossard | M | 50 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Oliver Günther | M | 54 | 6 years | |
| Christoph Koch | M | - | 4 years | |
| Harald F. Stock | M | 56 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Axel Hoos | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Mark Sumeray | M | 58 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | 6 years |
| Michael Albrecht | M | 74 |
Ruprecht-Karls-Universität Heidelberg
| 5 years |
| Yi Zhun Zhu | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Jochen Müller | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Ina Schlie | F | 57 |
Ruprecht-Karls-Universität Heidelberg
| 5 years |
| Angela Geerling | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 48 | 71.64% |
| United Kingdom | 19 | 28.36% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Markus Ziener
- Personal Network
